.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A06A_DrugsForConstipation.A06AD65_MacrogolCombinations.MacrogolCombinations .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A06A_DrugsForConstipation.A06AD65_MacrogolCombinations.MacrogolCombinations| name: | MacrogolCombinations |
| ATC code: | A06AD65 | route: | oral |
| n-compartments | 1 |
Macrogol (also known as polyethylene glycol) combinations are used primarily as osmotic laxatives to treat constipation and to facilitate bowel cleansing before diagnostic procedures such as colonoscopy. Macrogol is widely used and approved for these indications in many countries.
Pharmacokinetic parameters for macrogol combinations in healthy adult volunteers following oral administration.
Hruska, MW, et al., & Marsteller, DA (2024). Population Pharmacokinetics of Naloxegol in Pediatric Subjects Receiving Opioids. Clinical pharmacology in drug development 13(9) 974–984. DOI:10.1002/cpdd.1457 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39110083
Keating, GM, & Curran, MP (2003). Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 63(7) 701–730. DOI:10.2165/00003495-200363070-00008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12656650
Xu, C, et al., & Sniukiene, V (2013). Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C. European journal of clinical pharmacology 69(12) 2045–2054. DOI:10.1007/s00228-013-1574-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23975236